返回列表 回复 发帖

Gene Therapy Revives Cones Long After They Stop Working

Gene Therapy Revives Cones Long After They Stop Working September 26, 2011 - If you could do one thing for a person losing their vision to a retinal disease, saving their cones would be near the top of the list. That’s because cones are the retinal cells that provide vision most critical for independent living and quality of life. They enable people to drive, read and see the faces of loved ones. A Foundation-funded research collaboration from the The Institut de la Vision in Paris and the Friedrich Miescher Institute in Basel, Switzerland, is developing a gene therapy that revives degenerating cones, enabling them to regain their ability to respond to light and provide vision. The treatment also improves the health of cones and extends their lifespan significantly. A key benefit of the approach is that it may help people affected by a range of conditions, because it works independently of the underlying disease-causing genetic defect. The collaboration’s goal is to move the gene therapy into a clinical trial within three years. In 2010, the investigative team showed that their treatment was effective and well sustained in both slow and fast models of retinal degeneration in mice. The scientists performed visual behavior and retinal sensitivity tests to demonstrate that the mice regained functional vision after treatment. The therapy involves delivery of a gene to cones that leads to the production of a microbial protein called halorhodopsin, which restores light sensitivity. In retinal degenerative conditions, such as retinitis pigmentosa, cones remain present for a long time after they stop working. To move the treatment into the clinic, the researchers will test the treatment in large animal models and adapt it for use in humans. The team is already putting together a patient screening protocol — which includes imaging, visual field testing and evaluation of retinal sensitivity — to identify people who may be eligible for the forthcoming clinical trial. The Foundation is providing nearly $1.5 million in funding over three years for the project

原文地址 http://www.blindness.org/retinitis-pigmentosa/2877-gene-therapy-revives-cones-long-after-they-stop-working-
早上和土豆博士在聊这篇文章,故意不发上来,看看有没有人发,呵呵 真的有人发了 谢谢楼主,下面是土豆博士的翻译内容。

这个研究是法国和瑞士合作研究的。

往视锥细胞中导入一种基因,表达出haloRHO蛋白,可以重新建立光感受能力

导入的基因表达的蛋白名字叫halorhodopsin,实际上就是一种RHO蛋白

查了下这个蛋白的来源,最初发现于嗜盐古菌,halorhodopsin是一种氯离子视紫红质蛋白

这个研究中,是将haloRHO基因导入到视锥细胞中,恢复感光能力 haloRHO基因疗法是针对视锥细胞依然存在,仅丧失了感光功能
这种方法是不是对无论任何基因突变引起的视网膜病变都有效,还是只对一种特定的基因突变有效果?
haloRHO基因疗法是针对视锥细胞依然存在,哪视锥细胞营养不良也算是视锥细胞存在吧
谢谢楼主分享,不知离我们还有多远
对必然之事,切轻快地加以承受。
这就是以前所说的的法国领导的Rdcvf疗法
谢谢楼主的分享,谢谢飞狐和土豆博士的翻译!
谢谢飞狐和土豆博士的翻译
本帖最后由 陶黎 于 2011-9-28 23:40 编辑

4# dhaokai
我也不是看的很明白,呵呵
顶掉卖枪的。
期待有一天能飞翔!
返回列表